The invention is concerned with novel hexafluoroisopropanol substituted ether derivatives of formula (I): ##STR00001## wherein R.sup.1 to R.sup.3 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.